Emcure Pharmaceuticals shares soared over 5% after Kotak Securities upgraded the stock to a “Buy” rating, raising the target price to ₹1,680. The brokerage cited robust growth potential, driven by a strong H2 FY25 outlook, rising PCPM metrics, and operational efficiencies. Key catalysts include its in-licensing deal with Sanofi, the successful integration of Mantra, and lower interest costs.
With a projected 29% CAGR in earnings per share, Emcure is well-positioned for sustained growth, making it a compelling investment in the pharma sector.
As of 9:28 am, Emcure Pharmaceuticals shares were trading 5.77% higher at Rs 1,387.70 on the NSE.
Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information.
